Generate Biomedicines, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Generate Biomedicines reported a net loss of $216.6 million for the first nine months of 2026, with cash reserves expected to last into mid-2028, highlighting ongoing capital requirements.